ABVC BIOPHARMA, INC. ABVC
breakthrough products and technologies to combat various diseases through efficient industrial manufacturing. Biotechnology is an important
business sector in the world's economies and is vital to human health. Companies engaged in biotechnology generally require
large amounts of capital investment for their research & development activities. Developing and commercializing a new drug or medical
device may take up to tens of years. ABVC ("we" or the "Company") is an early-stage biotechnology company with
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $296.0K | $0 | $152.4K | $969.8K | $355.8K | $483.0K | $701.7K | $7.0K | — | — |
| Cost of revenue | — | $763 | $302.0K | $286.4K | $5.1K | $18.7K | $20.1K | $185.3K | — | $32 |
| Gross profit | — | $508.8K | -$149.6K | $683.4K | $350.7K | $464.3K | $681.6K | -$178.3K | — | -$32 |
| R&D | $121.1K | $179.3K | $1.1M | $2.7M | $1.0M | $549.7K | $1.0M | $988.7K | $3.2M | $10.0M |
| SG&A | $2.9M | $2.3M | $5.4M | $6.1M | $5.7M | $4.3M | $3.1M | $1.6M | $811.7K | $599.3K |
| Total operating expenses | $7.2M | $5.2M | $6.6M | $15.8M | $12.1M | $9.0M | $4.1M | $2.6M | $4.1M | — |
| Operating income | -$7.2M | -$4.7M | -$6.8M | -$15.1M | -$11.7M | -$8.5M | -$3.5M | -$2.8M | -$4.1M | -$11.0M |
| Interest expense | $415.9K | $825.9K | $1.3M | $294.0K | $227.2K | $405.0K | $482.0K | $462.8K | $103.5K | $10.2K |
| Pre-tax income | -$8.4M | -$5.4M | -$8.0M | -$15.5M | -$11.2M | -$10.8M | -$4.0M | -$6.4M | -$4.2M | -$11.0M |
| Income tax | $24.2K | $110.5K | $256.0K | $797.8K | $825.0K | $220.4K | $77.0K | $365.1K | $830 | $836 |
| Net income | -$7.9M | -$4.9M | -$7.8M | -$16.4M | -$12.8M | -$10.6M | -$3.9M | -$6.1M | -$4.2M | -$11.0M |
| EPS, basic | -0.39 | -0.42 | -1.80 | -5.19 | -0.51 | -0.50 | — | -0.02 | -0.02 | -0.06 |
| EPS, diluted | -0.39 | -0.42 | -1.80 | -5.19 | -0.51 | -0.50 | -0.21 | -0.48 | -0.02 | -0.06 |
| Shares, diluted (wtd. avg.) | $20.1M | $11.7M | $4.3M | $3.2M | $25.1M | $19.7M | — | $213.9M | $213.3M | $194.0M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $681.5K | $248.4K | $716.8K | $1.4M | $6.6M | $5.0M | $160.4K | $242.8K | $406.8K | $18.6K |
| Short-term investments | $64.4K | $64.7K | $79.3K | $75.8K | $108.1K | — | — | — | — | — |
| Receivables | — | — | $1.5K | $98.3K | $280.7K | $159.7K | — | — | — | — |
| Inventory | — | — | — | — | $26.0K | — | — | $1.3K | — | — |
| Total current assets | $2.5M | $2.2M | $1.7M | $3.0M | $7.7M | $6.2M | $878.2K | $566.5K | $2.6M | $173.5K |
| Property, plant and equipment | $12.8M | $511.1K | $569.3K | $574.0K | $525.9K | $514.8K | $520.9K | $510.1K | — | — |
| Total assets | $21.1M | $7.5M | $7.8M | $9.6M | $13.7M | $11.6M | $6.9M | $5.9M | $2.6M | $177.4K |
| Accounts payable | — | — | — | — | — | $23.0K | $24.0K | — | — | — |
| Short-term debt | $755.5K | $840.3K | $899.2K | $1.9M | $1.6M | $1.6M | $1.9M | $899.2K | — | — |
| Total current liabilities | $6.2M | $6.6M | $6.1M | $5.5M | $3.7M | $4.8M | $6.8M | $11.0M | $4.4M | — |
| Total liabilities | $7.8M | $6.8M | $6.5M | $6.3M | $4.8M | $8.9M | $7.1M | $11.3M | $4.4M | $6.6M |
| Retained earnings | -$76.9M | -$68.9M | -$64.0M | -$54.9M | -$38.5M | -$25.6M | -$15.9M | -$12.2M | -$15.8M | -$11.3M |
| Total equity | $11.1M | $1.2M | $1.3M | $3.2M | $8.9M | $2.7M | -$124.8K | -$5.3M | $703.3K | -$6.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.0M | -$1.8M | -$4.2M | -$7.4M | -$7.6M | -$4.6M | -$3.1M | -$900.5K | -$1.5M | -$3.5M |
| Depreciation and amortisation | $25.3K | $32.0K | $28.5K | $23.8K | $12.0K | $37.1K | $55.1K | $43.6K | — | — |
| Stock-based compensation | $4.1M | $2.8M | $185.9K | $7.0M | $5.3M | $4.1M | $22.3K | $28.8K | $155.4K | $398.0K |
| Capital expenditure | — | — | $21.2K | $119.7K | $17.5K | — | — | — | — | — |
| Investing cash flow | -$1.2M | — | -$360.2K | -$1.7M | -$806.0K | -$225.4K | -$35.3K | -$156.4K | — | — |
| Financing cash flow | $4.6M | $2.0M | $3.9M | $4.0M | $10.0M | $9.6M | $3.1M | $896.9K | $1.6M | $2.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-023063.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |